Comparison of AML Samples and Normal Bone Marrow Myeloid Cells With Respect to the Effects of Treatments on Sub-G1 Apoptosis and BCL-2 Positivity
| Measure . | AML Samples . | Control Myeloid-Enriched Samples From Normal Bone Marrows . | |||||
|---|---|---|---|---|---|---|---|
| . | Treatment . | N . | Mean Change . | 95% CI . | N . | Mean Change . | 95% CI . |
| % G1 apoptosis | DNR | 43 | +0.6 | −0.1-1.4 | 6 | +2.2 | −1.5-5.8 |
| ARA-C | 56 | +2.5 | 1.6-3.3 | 6 | +15.0 | 7.2-22.8 | |
| RAD | 52 | +4.3 | 2.7-5.8 | 6 | +15.2 | 9.2-21.0 | |
| % BCL-2–positive | DNR | 31 | +0.6 | −1.6-2.9 | 5 | +7.6 | 3.8-11.4 |
| ARA-C | 31 | +2.2 | 0.4-7.7 | 4 | +8.8 | 5.1-12.5 | |
| RAD | 31 | +2.2 | −1.7-5.7 | 4 | +13.8 | 5.8-16.7 | |
| Measure . | AML Samples . | Control Myeloid-Enriched Samples From Normal Bone Marrows . | |||||
|---|---|---|---|---|---|---|---|
| . | Treatment . | N . | Mean Change . | 95% CI . | N . | Mean Change . | 95% CI . |
| % G1 apoptosis | DNR | 43 | +0.6 | −0.1-1.4 | 6 | +2.2 | −1.5-5.8 |
| ARA-C | 56 | +2.5 | 1.6-3.3 | 6 | +15.0 | 7.2-22.8 | |
| RAD | 52 | +4.3 | 2.7-5.8 | 6 | +15.2 | 9.2-21.0 | |
| % BCL-2–positive | DNR | 31 | +0.6 | −1.6-2.9 | 5 | +7.6 | 3.8-11.4 |
| ARA-C | 31 | +2.2 | 0.4-7.7 | 4 | +8.8 | 5.1-12.5 | |
| RAD | 31 | +2.2 | −1.7-5.7 | 4 | +13.8 | 5.8-16.7 | |
Sub-G1 apoptosis and BCL-2 positivity data were collected in multiparameter, flow cytometic analyses performed after treatments with therapeutic agents as described in the text. The numbers of samples in each treatment group are noted (N). Mean changes are averages of treated values with untreated values subtracted for each AML and control myeloid cell sample. Confidence intervals (95% CI) are based on 2 sample t-tests, using the approximation of Cochran and Cox to adjust for unequal variances. The mean changes in AML v normal myeloid cell responses to ARA-C and RAD were significantly different (P = .025).